The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.

Factor V Leiden (FVL) and prothrombin G20210A mutation (PTM) are the two most common genetic polymorphisms known to predispose to a first episode of venous thromboembolism (VTE). However, whether these thrombophilic abnormalities are also risk factors for recurrent VTE is unclear. We conducted a systematic review of prospective studies to assess the risk of recurrent VTE associated with heterozygous carriage of each of these mutations. All randomized controlled trials and prospective cohort studies that reported the incidence of recurrent VTE in patients with and without FVL and PTM after discontinuation of anticoagulant treatment were collected and analyzed. The risk ratios (RR) and their 95% confidence intervals (CI) for recurrent VTE were calculated in heterozygous carriers of FVL or PTM and compared to those of non-carriers. Eleven studies fulfilled the inclusion criteria. Recurrent VTE occurred in 114 out of 557 heterozygous carriers of FVL (20.5%) as compared to 382 out of 2,646 non-carriers (14.4%); and in 38 out of 212 heterozygous carriers of PTM (17.9%) compared to 428 of 2,996 non-carriers (14.3%). The RR of VTE recurrence conferred by the heterozygous carriage of FVL and PTM was 1.39 (95% CI, range 1.15 to 1.67) and 1.20 (range 0.89 to 1.61), respectively, using the Mantel-Haenszel fixed-effects model; 1.45 (1.13 to 1.85) and 1.36 (1.02 to 1.82), respectively, using the Der Simonian and Laird random effects method. In symptomatic patients with VTE, heterozygous carriage of FVL is clearly associated with a definitely increased risk of recurrent thromboembolism. The risk is lower with PTM and is difficult to interpret since it varies according to the assessment method used.

[1]  G. Hankey,et al.  Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. , 2006, Archives of internal medicine.

[2]  J. Miguel,et al.  Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[3]  Frits R Rosendaal,et al.  Thrombophilia, clinical factors, and recurrent venous thrombotic events. , 2005, JAMA.

[4]  A. Nicolaides,et al.  Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. , 2005, International angiology : a journal of the International Union of Angiology.

[5]  W. Ageno,et al.  Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. , 2005, Thrombosis research.

[6]  Giancarlo Agnelli,et al.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[7]  H. Büller,et al.  Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model , 2003, Journal of thrombosis and haemostasis : JTH.

[8]  B. Giusti,et al.  Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. , 2003, The American journal of medicine.

[9]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[10]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[11]  F. Bernardi,et al.  Predictive Value of D‐Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia , 2003, Circulation.

[12]  I. Greer.  Inherited thrombophilia and venous thromboembolism. , 2003, Best practice & research. Clinical obstetrics & gynaecology.

[13]  P. Ridker,et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[14]  J. Kelton,et al.  Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System , 2003, Annals of Internal Medicine.

[15]  Klaus Lechner,et al.  The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. , 2002, Archives of internal medicine.

[16]  H. Blom,et al.  Interaction Between Hyperhomocysteinemia, Mutated Methylenetetrahydrofolatereductase (MTHFR) and Inherited Thrombophilic Factors in Recurrent Venous Thrombosis , 2002, Thrombosis and Haemostasis.

[17]  S. Eichinger,et al.  The risk of recurrent venous thromboembolism. , 2002, VASA. Zeitschrift fur Gefasskrankheiten.

[18]  M. Prins,et al.  The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders , 2002, British journal of haematology.

[19]  K. Bauer.  The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications , 2001, Annals of Internal Medicine.

[20]  G Leone,et al.  The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. , 2001, British journal of haematology.

[21]  P. Ridker,et al.  G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. , 2001, Journal of the American College of Cardiology.

[22]  M. Prins,et al.  Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. , 2000, Blood.

[23]  G. Barosi,et al.  Extended Anticoagulation for Prevention of Recurrent Venous Thromboembolism in Carriers of Factor V Leiden , 2000, Thrombosis and Haemostasis.

[24]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[25]  M. Prins,et al.  Recurrent deep vein thrombosis and two coagulation factor gene mutations: quo vadis? , 1999, Thrombosis and haemostasis.

[26]  M. Margaglione,et al.  Coexistence of Factor V Leiden and Factor II A20210 Mutations and Recurrent Venous Thromboembolism , 1999, Thrombosis and Haemostasis.

[27]  B. Wiman,et al.  The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[28]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[29]  E. Minar,et al.  The Risk of Early Recurrent Venous Thromboembolism after Oral Anticoagulant Therapy in Patients with the G20210A Transition in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[30]  E. Minar,et al.  The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden , 1997, Thrombosis and Haemostasis.

[31]  A. Berrebi,et al.  Causes and outcome of deep-vein thrombosis in otherwise-healthy patients under 50 years. , 1997, QJM : monthly journal of the Association of Physicians.

[32]  M. Prins,et al.  The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). , 1997, The New England journal of medicine.

[33]  A. Nicolaides,et al.  Prevention of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). , 1997, International angiology : a journal of the International Union of Angiology.

[34]  C. Mannhalter,et al.  Probability of Recurrence of Thrombosis in Patients with and without Factor V Leiden , 1996, Thrombosis and Haemostasis.

[35]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[36]  R. Hull,et al.  Antithrombotic therapy for venous thromboembolic disease. , 1995, Chest.

[37]  R. Hull,et al.  Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.

[38]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[39]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.